{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Garcia A"],"funding":["GlaxoSmithKline"],"pubmed_abstract":["The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66-80 years, starting with 80 years. However, the risk of herpes zoster (HZ) increases significantly from 50 years. We estimated the public health impact (PHI) of vaccinating adults ≥50 years in Spain versus no vaccination, using a Markov model adapted to the Spanish setting. The model simulated a hypothetical ≥50 years cohort over a lifetime, with inputs from Spanish publications, databases, or publications from other countries where Spanish data were unavailable. Base case inputs included 67.7% RZV coverage and 61.1% second dose compliance. Outputs included clinical outcomes avoided, healthcare resourc"],"journal":["Human vaccines & immunotherapeutics"],"pagination":["2366353"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11210909"],"repository":["biostudies-literature"],"pubmed_title":["The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain."],"pmcid":["PMC11210909"],"pubmed_authors":["Vallejo-Aparicio LA","Cambronero Martinez R","Garcia A"],"additional_accession":[]},"is_claimable":false,"name":"The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain.","description":"The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66-80 years, starting with 80 years. However, the risk of herpes zoster (HZ) increases significantly from 50 years. We estimated the public health impact (PHI) of vaccinating adults ≥50 years in Spain versus no vaccination, using a Markov model adapted to the Spanish setting. The model simulated a hypothetical ≥50 years cohort over a lifetime, with inputs from Spanish publications, databases, or publications from other countries where Spanish data were unavailable. Base case inputs included 67.7% RZV coverage and 61.1% second dose compliance. Outputs included clinical outcomes avoided, healthcare resourc","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Dec","modification":"2025-04-19T18:33:19.89Z","creation":"2025-04-19T18:33:19.89Z"},"accession":"S-EPMC11210909","cross_references":{"pubmed":["38925145"],"doi":["10.1080/21645515.2024.2366353"]}}